Tirofiban
- Generic Name
- Tirofiban
- Brand Names
- Aggrastat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H36N2O5S
- CAS Number
- 144494-65-5
- Unique Ingredient Identifier
- GGX234SI5H
- Background
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
- Indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
- Associated Conditions
- Cardiovascular Events
- Associated Therapies
- -
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03114995
Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Inova Health Care Services
- Target Recruit Count
- 10
- Registration Number
- NCT03048019
- Locations
- 🇺🇸
Inova Health Care System, Falls Church, Virginia, United States
Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 122
- Registration Number
- NCT02978040
- Locations
- 🇨🇭
Bern University Hospital, Bern, Switzerland
🇮🇹University of Ferrara, Ferrara, Italy
🇮🇹University of Naples Federico II, Naples, Italy
Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Second Hospital of Jilin University
- Target Recruit Count
- 1000
- Registration Number
- NCT02294994
- Locations
- 🇨🇳
The sencond hospital of Jilin University, Changchun, Jilin, China
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 362
- Registration Number
- NCT02131220
- Locations
- 🇨🇳
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Intracoronary Tirofiban on No-Reflow Phenomena
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- TC Erciyes University
- Target Recruit Count
- 162
- Registration Number
- NCT02054000
- Locations
- 🇹🇷
Erciyes University School of Medicine, Kayseri, Turkey
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Medicure
- Target Recruit Count
- 25
- Registration Number
- NCT01766154
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01660373
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Kyeongsangnamdo, Korea, Republic of
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-05-15
- Target Recruit Count
- 200
- Registration Number
- NCT01598337
- Locations
- 🇸🇦
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
Tirofiban in Stenting for Long Coronary Lesion
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 748
- Registration Number
- NCT01498003
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.